Mission Core Values Corporate Brochure

Rapid Test Applications Rapid HIV Tests H. Pylori Multiple Tests Research Tools Quality Commitment

Core Technology Features & Functionality IP Estate

Media Resources Media Contacts

Distributors & Partners

Intellectual Property Estate

MedMira believes that their rapid flow-through technology (RFT) platform and the methodology behind their rapid diagnostics are among the Company's most valuable assets. As such, MedMira has taken steps to protect these assets with patents in key international markets. Several key patents have been awarded to MedMira and others are pending.

MedMira's intellectual property (IP) estate includes the following:

United States

Patent No. 10/163,675

European Union

European Patent Application No. EP1417489

China

Chinese Patent No. 02819646.5

Product Benefits

Most advanced rapid diagnostics

FDA, CE and China approved

Instant results

Easy for mass testing

Single & multiple disease tests

Patented Technology

Decreased costs

A safer world!